Abstract
Abstract Several drugs have recently been shown to be active in inhibiting the antigenically induced in vitro release of compounds thought to be involved in anaphylactic reactions. These compounds offer interesting tools with which to study the mechanism of the reactions of immediate hypersensitivity as well as having the potential for therapeutic use in man. Of the drugs already in use in man diethylcarbamazine (Hetrazan), an antifilarial agent, inhibits the release of the slow reacting substance of anaphylaxis (SRS-A) from rat peritoneal leukocytes (1) while disodium chromoglycate (Intal) inhibits the release of histamine from rat mast cells in vivo (2). The latter, however, does not inhibit in vitro histamine release from human leukocytes (L. M. Lichtenstein, unpublished). Both of these drugs are currently being studied for their usefulness in the treatment of human asthma (3, 4). Recently, drugs of the catecholamine and methylxanthine series were shown to inhibit the release of histamine from human leukocytes: evidence was presented to suggest that they operated through the cyclic 3′5′ AMP system (5, 6).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
